Welcome to our dedicated page for Numinus Wellness news (Ticker: NUMIF), a resource for investors and traders seeking the latest updates and insights on Numinus Wellness stock.
News and updates for Numinus Wellness Inc. (NUMIF) focus on its activities as a mental health care company centered on safe, evidence-based psychedelic-assisted therapies. Company announcements consistently describe efforts to advance behavioral health treatments through clinical trial research, practitioner training and technology-driven support for clinic-based delivery of psychedelic-assisted therapy.
Readers of the Numinus news feed can expect coverage of financial results, including quarterly updates that discuss revenue trends, gross margin, operating expenditures and cash position. These releases often highlight performance at Cedar Clinical Research, where Numinus manages clinical trials and provides research services for drug sponsors, as well as metrics related to its practitioner training business.
Corporate news also includes strategic and organizational developments. Numinus has reported the sale of its U.S. clinic network, the wind-down of non-operating subsidiaries through bankruptcy, and leadership changes such as the appointment of a new Chief Executive Officer and transitions in the Chief Financial Officer role. Additional updates describe accreditation milestones for its Psychedelic-Assisted Therapy Training Program in jurisdictions such as Oregon and Colorado, and engagements like Cedar Clinical Research’s participation in a Phase 3 multinational trial for CYB003 targeting Major Depressive Disorder.
Regulatory and capital markets developments are another recurring theme. Numinus has issued news about a cease trade order affecting its shares, its application to the British Columbia Securities Commission for revocation, and its stated intention to pursue relisting on another reputable exchange once conditions permit. For investors and observers, following NUMIF news provides insight into the company’s operational focus, restructuring steps, regulatory progress and evolving role in the psychedelic-assisted therapy ecosystem.
Numinus Wellness has launched a new clinic licensing model called the Numinus Network, allowing independent practitioners to operate clinics under its brand. This model aims to reduce capital investment while expanding access to psychedelic-assisted therapies across North America. The company has partnered with Healing Commercial Real Estate Inc. to provide licensees with turn-key locations, enhancing operational support and clinic infrastructure. Numinus aims to advocate for more accessible treatment options, compelling practitioners to join their network while retaining independence. The licensing fees and investment costs will vary based on individual arrangements and locations.
Numinus Wellness Inc. (TSX: NUMI, OTCQX: NUMIF) will announce its Q2 2023 financial results on April 13, 2023, after market close. A conference call and webcast will follow at 5:30 p.m. Eastern time, where executives will discuss company performance and recent initiatives. Interested participants can register for the live webcast here. A replay will be available post-event until April 27, 2023. Numinus, focused on evidence-based psychedelic-assisted therapies, aims to transform mental health care by integrating these therapies into mainstream practice.
Numinus Wellness (TSX: NUMI) (OTCQX: NUMIF) has launched the Numinus Certification Pathway, a comprehensive training program for psychedelic-assisted therapy (PAT). This initiative includes courses that develop core PAT skills through various teaching methods, ensuring practitioners gain competency in using psychedelic medications. Notably, over 200 practitioners have already participated in Numinus training since its inception in Fall 2022. The most sought-after course, The Fundamentals of Psychedelic-Assisted Therapy, begins its next intake in May 2023, emphasizing evidence-based care and safety. The program aims to enhance the quality of mental health services provided by trained professionals.
Numinus Wellness Inc. (TSX: NUMI) (OTCQX: NUMIF) will participate in the Sequire Cannabis & Psychedelics Conference on April 5, 2023. The company's Founder and CEO, Payton Nyquvest, is set to present at 10:00 a.m. ET. Interested attendees can register for the virtual event here.
Numinus specializes in innovative mental health treatments, including psychedelic-assisted therapies, to promote healing for conditions such as depression, anxiety, and trauma. For more information, contact invest@numinus.com.
Numinus Wellness Inc. (TSX: NUMI) (OTCQX: NUMIF) announced contributions from Chief Clinical Officer Reid Robison, who published four peer-reviewed papers in 2023 about innovative mental health treatments. These studies focus on conditions such as PTSD, depression, and anxiety, showcasing advancements in psychedelic-assisted therapies. Key highlights include the effectiveness of ketamine-assisted psychotherapy for healthcare workers with PTSD, the positive impact of cannabis-assisted psychotherapy, and promising breathwork interventions for anxiety. Numinus aims to integrate evidence-based treatments into mainstream clinical practice, propelling the mental health sector forward.
Numinus Wellness Inc. (TSX: NUMI; OTCQX: NUMIF) will be featured at the upcoming South by Southwest Conference in Austin, Texas, from March 10 to 19, 2023. CEO Payton Nyquvest will be on a panel titled "Music as Medicine: Music as a Tool For Healing" on March 10 at 4:00 PM CT. The discussion will focus on the role of music in psychedelic healing, highlighting its importance in therapy. This event is part of Numinus' Music as Medicine program, which emphasizes the connection between music and mental health. Numinus aims to advance innovative, evidence-based psychedelic-assisted therapies for mental health care.
Numinus Wellness (TSX: NUMI; OTCQX: NUMIF) announced Dr. Paul Thielking, Chief Science Officer, will join a Water Tower Research Fireside Chat on February 28, 2023, at 3:00 p.m. ET. The discussion will cover Numinus' clinical research activities at Cedar Clinical Research and the new research site in Phoenix, Arizona. This engagement highlights Numinus' commitment to advancing evidence-based psychedelic-assisted therapies aimed at improving mental health. Interested parties can register here.
Numinus Wellness has announced the opening of its third research facility in the US, located in Phoenix, Arizona, enhancing its clinical research capabilities. This site, which is Numinus' fifth overall research facility, aims to streamline recruitment and clinical trial management for partners in the psychedelic therapy sector. The first clinical trial will commence in early March 2023. In the last quarter, Numinus managed 14 clinical trials, involving 191 participants. The expansion is expected to solidify Numinus' position as a leading research platform in mental health, focusing on evidence-based psychedelic-assisted therapies.
Numinus Wellness Inc. (TSX: NUMI; OTCQX: NUMIF) held its Annual General and Special Meeting of Shareholders on February 15, 2023, with 43,610,863 shares (16.6% of the total) represented. Five proposed nominees were elected as Directors for the upcoming term. Notably, Payton Nyquvest received 85.26% approval, while Edwin Garner garnered 98.48%. Shareholders also approved the appointment of Davidson & Company LLP as auditors and the Omnibus Equity Incentive Plan. The outcomes were detailed in the Management Information Circular dated January 18, 2023, available on SEDAR.
Numinus Wellness has received approval from Health Canada for a groundbreaking clinical trial studying the safety and efficacy of whole Psilocybe cubensis tea, branded as EnfiniTea. This trial is historic as it is the first to evaluate whole mushrooms in a clinical environment, aiming to enhance access to psilocybin-assisted therapy. The study will also offer experiential training for therapists, ensuring a skilled workforce for future treatments. The trial will take place at Numinus' Vancouver clinic, with initial results anticipated in the second half of 2023.